Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Cash & Equivalents (2020 - 2025)

Sight Sciences has reported Cash & Equivalents over the past 6 years, most recently at $92.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $92.0 million for Q4 2025, down 23.59% from a year ago — trailing twelve months through Dec 2025 was $92.0 million (down 23.59% YoY), and the annual figure for FY2025 was $92.0 million, down 23.59%.
  • Cash & Equivalents for Q4 2025 was $92.0 million at Sight Sciences, roughly flat from $92.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for SGHT hit a ceiling of $271.5 million in Q3 2021 and a floor of $35.6 million in Q2 2021.
  • Median Cash & Equivalents over the past 5 years was $138.1 million (2023), compared with a mean of $152.4 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 518.74% in 2022 and later fell 29.86% in 2023.
  • Sight Sciences' Cash & Equivalents stood at $260.7 million in 2021, then dropped by 29.03% to $185.0 million in 2022, then dropped by 25.34% to $138.1 million in 2023, then dropped by 12.87% to $120.4 million in 2024, then dropped by 23.59% to $92.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $92.0 million (Q4 2025), $92.4 million (Q3 2025), and $101.5 million (Q2 2025) per Business Quant data.